Sutura Therapeutics is a biopharmaceutical company at the forefront of developing next-generation biomolecular medicines. Through its innovative PeptiGo technology platform, Sutura is advancing the field of biomolecular medicine to address the unmet medical needs of patients with diseases that were previously considered undruggable. Biomolecule-based medicines have unique biological properties and actions, which make them promising in treating diseases. However, the size and shape of biomolecules often limit their capacity to enter cells and reach their target, making them less effective. Sutura’s proprietary PeptiGo platform is designed to overcome these limitations and has the potential to address a broad range of indications.